EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Novel Aerogel Delivery System Reduces Drug Resistance for Non‐Small Cell Lung Cancer Combination Therapy

Dingwei Diao iD, Yu Tong iD, Jianxue Zhai iD, Shijie Mai iD, Xiguang Liu iD, Xuguang Rao iD, Kaican Cai iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.72139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Dingwei Diao und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aerogels, Lung Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Natural Science Foundation, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lung cancer remains the leading cause of cancer‐related mortality, with non‐small cell lung cancer (NSCLC) representing the predominant subtype. Despite advances with molecularly targeted therapies, the prognosis remains poor because of drug resistance. Combination therapy with docetaxel and gefitinib offers synergistic potential but is limited by systemic side effects from nonspecific uptake. Here, we developed an inhalable aerogel‐based nanocarrier for the efficient codelivery of docetaxel and gefitinib, designed to enhance lung tumor accumulation while reducing systemic toxicity. Inhalation administration resulted in significant drug enrichment in tumors and achieved a tumor inhibition rate of 55.4% ± 3.6% in an NSCLC xenograft model, with reduced resistance compared with monotherapy. Mechanistically, the aerogel synergistically suppressed angiogenesis and promoted apoptosis. These findings underscore the potential of inhalable aerogels as a promising strategy for effective NSCLC therapy and clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAerogelsLung NeoplasmsDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsDrug Delivery SystemsHumansAnimalsDocetaxelXenograft Model Antitumor AssaysMiceGefitinibCell Line, TumorApoptosisFemale

Stichwörter der Autor:innen

combination therapynano‐carriernebulized aerogelnon‐small cell lung cancer (NSCLC)

Substanzen

AerogelsDocetaxelGefitinib

Autor:innen und Institutionen

  • The Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

ORCID-Profile: Dingwei Diao, Yu Tong, Jianxue Zhai, Shijie Mai, Xiguang Liu, Xuguang Rao, Kaican Cai

Förderung

  • Beijing Natural Science Foundation
  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Diao, D., Tong, Y., Zhai, J., Mai, S., Liu, X., Rao, X., & Cai, K. (2026). A Novel Aerogel Delivery System Reduces Drug Resistance for Non‐Small Cell Lung Cancer Combination Therapy. Cancer Medicine. https://doi.org/10.1002/cam4.72139

Vancouver

Diao D, Tong Y, Zhai J, Mai S, Liu X, Rao X, et al. A Novel Aerogel Delivery System Reduces Drug Resistance for Non‐Small Cell Lung Cancer Combination Therapy. Cancer Medicine. 2026. doi:10.1002/cam4.72139

BibTeX
@article{Diao2026,
  author = {Diao, Dingwei and Tong, Yu and Zhai, Jianxue and Mai, Shijie and Liu, Xiguang and Rao, Xuguang and Cai, Kaican},
  title = {A Novel Aerogel Delivery System Reduces Drug Resistance for Non‐Small Cell Lung Cancer Combination Therapy},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72139}
}
Kostenlos starten →